Tamoxifen 20 mg EGIS 30 tab.

Tamoxifen 20 mg EGIS 30 tab is a drug used in the treatment of breast cancer. It belongs to a group of drugs called selective estrogen receptor modulators (SERMS). This drug blocks the action of estrogen in breast tissue, which helps slow the growth and spread of cancer cells. Tamoxifen 20 mg EGIS is available in tablet form and should be taken as prescribed by a doctor. It is an effective and widely used drug for the treatment of breast cancer, and has been shown to help improve patient survival rates.

Active ingredient:

Tamoxifen

Indications for use

Estrogen-dependent breast cancer in women (especially in menopause) and breast cancer in men after castration.

The drug can be used to treat ovarian cancer, endometrial cancer, kidney cancer, melanoma, soft tissue sarcomas with estrogen receptors in the tumor, as well as to treat prostate cancer with resistance to other drugs.

Contraindications

- Hypersensitivity to tamoxifen and / or any other ingredient of the drug,

- Thrombophlebitis,

- Pregnancy and breastfeeding,

- Use with caution in the treatment of patients with kidney pathology, diabetes mellitus, ophthalmological diseases, thromboembolic disorders in the anamnesis, hyperlipidemia, leukopenia, thrombocytopenia, hypercalcemia.

Method of administration and dosage

The dosage regimen is usually set individually depending on the indications. The daily dose is 20-40 mg.

The standard dose is 20 mg of tamoxifen orally daily for a long time until signs of disease progression appear.

The tablets should be taken whole with a small amount of liquid during meals in one dose in the morning, or divided into two doses, morning and evening.

Side effects

When treating with tamoxifen, the most common side effects are related to its antiestrogenic effect, manifested in the form of paroxysmal sensations of heat (hot flashes), vaginal bleeding or discharge, itching in the genital area, alopecia, pain in the affected area and in the bones.

Interaction with other drugs

When tamoxifen is prescribed simultaneously with cytostatics, the risk of thrombosis increases.

There are reports of tamoxifen potentiating the anticoagulant effect of coumarin drugs (eg, warfarin).

Medicines that reduce renal excretion of calcium, such as thiazide diuretics, may increase the risk of hypercalcemia.

There are two case reports of active chronic hepatitis and liver cirrhosis caused by the combined use of tamoxifen and tegafur.

Concomitant use of tamoxifen with other hormonal drugs (especially estrogen-containing contraceptives) leads to a weakening of the specific action of both drugs.

Special instructions

Women receiving tamoxifen should undergo regular gynecological examinations. If bloody vaginal discharge or vaginal bleeding occurs, the drug should be discontinued.

In patients with bone metastases, serum calcium concentrations should be determined periodically during the initial period of treatment. In case of severe disturbances, tamoxifen should be temporarily discontinued.

Tamoxifen can induce ovulation, which increases the risk of pregnancy, and therefore women who are sexually active during (and for approximately 2 months after) treatment with tamoxifen are advised to take a mechanical or non-hormonal contraceptive.

Manufacturer EGIS (Hungary)